\-\ Texto\\:\\ \ \(0\)\
\-\ the\\ patinet\\ is\\ a\\ cachectic\\,\\ jaundiced\\,\\ elderly\\ asian\\ female\\.\\ serum\\ total\\ bilirubin\\ 14\\.9mg\\/dl\\,\\ alkaline\\ phosphatase\\ 956\\ u\\/l\\.\ \(0\)\
\-\ \\>\\>\\ treatment\\ for\\ advanced\\ disease\\ usually\\ includes\\ chemotherapy\\ \\(traditionally\\ chop\\ although\\ this\\ is\\ evolving\\ and\\ has\\ changed\\ significantly\\ over\\ the\\ last\\ 30\\ years\\)\\.\\ \ \(0\)\
\-\ \\>\\>\\ other\\ interventions\\ are\\ usually\\ palliative\\,\\ as\\ in\\ this\\ case\\ where\\ percutaneous\\ biliary\\ drainage\\ followed\\ by\\ endobiliary\\ stenting\\ with\\ internal\\ drainage\\ was\\ performed\\.\ \(0\)\
\-\ \\>\\>\\ ct\\ liver\\:\\ infiltrative\\ mass\\ in\\ right\\ lobe\\ of\\ liver\\,\\ intrahepatic\\ biliary\\ dilatation\\,\\ lymphadenopathy\\.\ \(0\)\
\-\ \\>\\>\\ percutaneous\\ cholangiogram\\ and\\ external\\ biliary\\ drain\\ placement\\:\\ mildly\\ dilated\\ intrahepatic\\ biliary\\ ducts\\,\\ mass\\ effect\\ displaces\\ common\\ hepatic\\ duct\\.\ \(0\)\
\-\ \\>\\>\\ percutaneous\\ cholangiogram\\ and\\ endobiliary\\ stent\\ placement\\:\\ gore\\ viabil\\ covered\\ metallic\\ stent\\ allows\\ internal\\ drainage\\.\ \(0\)\
\-\ large\\ b\\ cell\\ lymphoma\\ of\\ the\\ liver\\ with\\ malignant\\ biliary\\ obstruction\ \(0\)\
\-\ \\>\\>\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ \\>\\>\\ cholangiocarcinoma\ \(0\)\
\-\ one\\ month\\ of\\ abdominal\\ pain\\,\\ nausea\\,\\ and\\ vomiting\\.\ \(0\)\
\-\ key\\ facts\\ for\\ biliary\\ stenting\\ of\\ malignant\\ obstructive\\ jaundice\\:\ \(0\)\
\-\ \\>\\>\\ it\\ is\\ palliative\\ therapy\\.\ \(0\)\
\-\ \\>\\>\\ metal\\ stents\\ demonstrate\\ longer\\ patency\\ than\\ plastic\\ \\(polyethylene\\)\\ stents\\ for\\ malignant\\ biliary\\ obstruction\\ \\(median\\ expected\\ patency\\:\\ 250\\ and\\ 110\\ days\\ respectively\\)\\.\ \(0\)\
\-\ \\>\\>\\ this\\ treatment\\ provides\\ significant\\ palliation\\ of\\ patient\\ symptoms\\ due\\ to\\ biliary\\ obstruction\\ and\\ is\\ cost\\-effective\\ in\\ patients\\ with\\ longer\\ than\\ 6\\ months\\ expected\\ survival\\ resulting\\ in\\ fewer\\ hospital\\ admissions\\.\ \(0\)\
\-\ \\>\\>\\ covered\\ endobiliary\\ stents\\ like\\ the\\ gore\\ viabil\\ used\\ in\\ this\\ case\\ have\\ good\\ patency\\ rates\\ in\\ malignant\\ biliary\\ obstruction\\ and\\ allow\\ endobiliary\\ drainage\\ into\\ the\\ small\\ bowel\\ which\\ is\\ desirable\\ for\\ outpatient\\ management\\ of\\ these\\ patients\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\>\\:\\ 0\\.22228357766088405\ \(0\)\
\-\ biliary\\:\\ 0\\.1382255472694879\ \(0\)\
\-\ endobiliary\\:\\ 0\\.12548780674685406\ \(0\)\
\-\ stents\\:\\ 0\\.06520428707684293\ \(0\)\
\-\ patency\\:\\ 0\\.06325779358793951\ \(0\)\
\-\ viabil\\:\\ 0\\.06274390337342703\ \(0\)\
\-\ gore\\:\\ 0\\.054924598827746536\ \(0\)\
\-\ drainage\\:\\ 0\\.05087219087411894\ \(0\)\
\-\ cholangiogram\\:\\ 0\\.049991166937640164\ \(0\)\
\-\ percutaneous\\:\\ 0\\.048310238250727125\ \(0\)\
\-\ malignant\\:\\ 0\\.043966842368388624\ \(0\)\
\-\ obstruction\\:\\ 0\\.04289537435714499\ \(0\)\
\-\ covered\\:\\ 0\\.04107470452842046\ \(0\)\
\-\ stenting\\:\\ 0\\.03955460417042716\ \(0\)\
\-\ palliative\\:\\ 0\\.037043420009411195\ \(0\)\
\-\ intrahepatic\\:\\ 0\\.035810169324186736\ \(0\)\
\-\ longer\\:\\ 0\\.03435255784627917\ \(0\)\
\-\ stent\\:\\ 0\\.03422195899454823\ \(0\)\
\-\ liver\\:\\ 0\\.031454322179708796\ \(0\)\
\-\ 14\\.9mg\\/dl\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ polyethylene\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ cost\\-effective\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ expected\\:\\ 0\\.02961963041856922\ \(0\)\
\-\ patinet\\:\\ 0\\.028905235741660328\ \(0\)\
\-\ 956\\:\\ 0\\.028905235741660328\ \(0\)\
\-\ facts\\:\\ 0\\.028905235741660328\ \(0\)\
\-\ admissions\\:\\ 0\\.027462299413873268\ \(0\)\
\-\ chop\\:\\ 0\\.02564441463178789\ \(0\)\
\-\ desirable\\:\\ 0\\.02564441463178789\ \(0\)\
\-\ cachectic\\:\\ 0\\.024995583468820082\ \(0\)\
\-\ placement\\:\\ 0\\.024686198528462842\ \(0\)\
\-\ palliation\\:\\ 0\\.023971803851553956\ \(0\)\
\-\ jaundiced\\:\\ 0\\.023552647141033018\ \(0\)\
\-\ fewer\\:\\ 0\\.023552647141033018\ \(0\)\
\-\ traditionally\\:\\ 0\\.023177698686734704\ \(0\)\
\-\ 250\\:\\ 0\\.023177698686734704\ \(0\)\
\-\ evolving\\:\\ 0\\.02283851655219974\ \(0\)\
\-\ 110\\:\\ 0\\.022244018030266766\ \(0\)\
\-\ plastic\\:\\ 0\\.02089352115587209\ \(0\)\
\-\ internal\\:\\ 0\\.02039057559700193\ \(0\)\
\-\ interventions\\:\\ 0\\.0202136092812717\ \(0\)\
\-\ \\:\\:\\ 0\\.02011165153008301\ \(0\)\
\-\ phosphatase\\:\\ 0\\.019916877576862266\ \(0\)\
\-\ metal\\:\\ 0\\.019916877576862266\ \(0\)\
\-\ asian\\:\\ 0\\.01977730208521358\ \(0\)\
\-\ alkaline\\:\\ 0\\.019388692505266987\ \(0\)\
\-\ changed\\:\\ 0\\.019268046413894457\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.019151356652958546\ \(0\)\
\-\ displaces\\:\\ 0\\.018928864279359494\ \(0\)\
\-\ provides\\:\\ 0\\.018822625976335716\ \(0\)\
\-\ allow\\:\\ 0\\.018822625976335716\ \(0\)\
\-\ allows\\:\\ 0\\.018719467482124854\ \(0\)\
\-\ u\\/l\\:\\ 0\\.018521710004705597\ \(0\)\
\-\ usually\\:\\ 0\\.018469240241044547\ \(0\)\
\-\ bilirubin\\:\\ 0\\.01833436575742652\ \(0\)\
\-\ jaundice\\:\\ 0\\.018156392730470428\ \(0\)\
\-\ metallic\\:\\ 0\\.017986897894209732\ \(0\)\
\-\ elderly\\:\\ 0\\.017905084662093368\ \(0\)\
\-\ key\\:\\ 0\\.017905084662093368\ \(0\)\
\-\ rates\\:\\ 0\\.01767035879806562\ \(0\)\
\-\ median\\:\\ 0\\.017595435633660523\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.017522057387387442\ \(0\)\
\-\ respectively\\:\\ 0\\.017522057387387442\ \(0\)\
\-\ infiltrative\\:\\ 0\\.01745016163180908\ \(0\)\
\-\ ducts\\:\\ 0\\.01745016163180908\ \(0\)\
\-\ outpatient\\:\\ 0\\.017310586140160393\ \(0\)\
\-\ drain\\:\\ 0\\.016742507330224865\ \(0\)\
\-\ survival\\:\\ 0\\.016303957008431454\ \(0\)\
\-\ than\\:\\ 0\\.01593629078233647\ \(0\)\
\-\ patients\\:\\ 0\\.015740744479473493\ \(0\)\
\-\ obstructive\\:\\ 0\\.01564654027106726\ \(0\)\
\-\ advanced\\:\\ 0\\.01556180486646328\ \(0\)\
\-\ significantly\\:\\ 0\\.01556180486646328\ \(0\)\
\-\ serum\\:\\ 0\\.01467676349372724\ \(0\)\
\-\ b\\:\\ 0\\.014334614523788087\ \(0\)\
\-\ like\\:\\ 0\\.014077245621369486\ \(0\)\
\-\ duct\\:\\ 0\\.013941916811443368\ \(0\)\
\-\ this\\:\\ 0\\.01368166851692716\ \(0\)\
\-\ resulting\\:\\ 0\\.013355599256012566\ \(0\)\
\-\ case\\:\\ 0\\.013306081372720787\ \(0\)\
\-\ total\\:\\ 0\\.013095088921410094\ \(0\)\
\-\ dilatation\\:\\ 0\\.013032835692059498\ \(0\)\
\-\ good\\:\\ 0\\.013012324287373556\ \(0\)\
\-\ last\\:\\ 0\\.012991930427199231\ \(0\)\
\-\ mildly\\:\\ 0\\.012951490004956117\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.012931440831581542\ \(0\)\
\-\ external\\:\\ 0\\.012931440831581542\ \(0\)\
\-\ hepatic\\:\\ 0\\.01269926815589328\ \(0\)\
\-\ where\\:\\ 0\\.01241153827465095\ \(0\)\
\-\ treatment\\:\\ 0\\.012310440993600619\ \(0\)\
\-\ includes\\:\\ 0\\.012259360839284111\ \(0\)\
\-\ nausea\\:\\ 0\\.012242847033033213\ \(0\)\
\-\ 30\\:\\ 0\\.011694268101263611\ \(0\)\
\-\ used\\:\\ 0\\.011666135789850396\ \(0\)\
\-\ vomiting\\:\\ 0\\.0116105296763163\ \(0\)\
\-\ management\\:\\ 0\\.011475200866390181\ \(0\)\
\-\ hospital\\:\\ 0\\.011448741868213961\ \(0\)\
\-\ dilated\\:\\ 0\\.011050147354418607\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01090016293644436\ \(0\)\
\-\ effect\\:\\ 0\\.010767111220886992\ \(0\)\
\-\ for\\:\\ 0\\.010378763681746834\ \(0\)\
\-\ although\\:\\ 0\\.010270210962906062\ \(0\)\
\-\ followed\\:\\ 0\\.010195287798500966\ \(0\)\
\-\ is\\:\\ 0\\.010005173992610777\ \(0\)\
\-\ bowel\\:\\ 0\\.009537201184643272\ \(0\)\
\-\ days\\:\\ 0\\.009320549096697429\ \(0\)\
\-\ month\\:\\ 0\\.00912318341921925\ \(0\)\
\-\ 6\\:\\ 0\\.009082278154358983\ \(0\)\
\-\ in\\:\\ 0\\.008997805625770568\ \(0\)\
\-\ years\\:\\ 0\\.008929690879069332\ \(0\)\
\-\ lymphoma\\:\\ 0\\.00869109834302308\ \(0\)\
\-\ \\,\\:\\ 0\\.008670429144681802\ \(0\)\
\-\ carcinoma\\:\\ 0\\.008618959679771767\ \(0\)\
\-\ performed\\:\\ 0\\.008478926445648821\ \(0\)\
\-\ mass\\:\\ 0\\.00845879720247377\ \(0\)\
\-\ months\\:\\ 0\\.008305840906370345\ \(0\)\
\-\ one\\:\\ 0\\.00824103695128343\ \(0\)\
\-\ cell\\:\\ 0\\.008214379756517745\ \(0\)\
\-\ lobe\\:\\ 0\\.008182652483713644\ \(0\)\
\-\ significant\\:\\ 0\\.008177391996634246\ \(0\)\
\-\ therapy\\:\\ 0\\.00813039429267122\ \(0\)\
\-\ due\\:\\ 0\\.008114865312999429\ \(0\)\
\-\ common\\:\\ 0\\.007958246305894652\ \(0\)\
\-\ these\\:\\ 0\\.007914038049672029\ \(0\)\
\-\ over\\:\\ 0\\.007742500320782784\ \(0\)\
\-\ \\(\\:\\ 0\\.007712046899400646\ \(0\)\
\-\ \\)\\:\\ 0\\.007617840129323542\ \(0\)\
\-\ abdominal\\:\\ 0\\.007601136078726389\ \(0\)\
\-\ symptoms\\:\\ 0\\.007578852230954231\ \(0\)\
\-\ into\\:\\ 0\\.007236036896653761\ \(0\)\
\-\ other\\:\\ 0\\.007009389853033624\ \(0\)\
\-\ small\\:\\ 0\\.007005605994238856\ \(0\)\
\-\ demonstrate\\:\\ 0\\.006998050325028614\ \(0\)\
\-\ it\\:\\ 0\\.006835759375562337\ \(0\)\
\-\ large\\:\\ 0\\.006649617195128397\ \(0\)\
\-\ have\\:\\ 0\\.006585188890978974\ \(0\)\
\-\ female\\:\\ 0\\.006251815912625742\ \(0\)\
\-\ has\\:\\ 0\\.00571067605158106\ \(0\)\
\-\ which\\:\\ 0\\.005676671128977041\ \(0\)\
\-\ by\\:\\ 0\\.005063597520444394\ \(0\)\
\-\ disease\\:\\ 0\\.004970596232084356\ \(0\)\
\-\ as\\:\\ 0\\.004599919949801167\ \(0\)\
\-\ and\\:\\ 0\\.004484210107208289\ \(0\)\
\-\ ct\\:\\ 0\\.0042537496561994405\ \(0\)\
\-\ are\\:\\ 0\\.004145458621101785\ \(0\)\
\-\ pain\\:\\ 0\\.0037139080695043937\ \(0\)\
\-\ was\\:\\ 0\\.003517001858411697\ \(0\)\
\-\ right\\:\\ 0\\.0032086537690762156\ \(0\)\
\-\ patient\\:\\ 0\\.0030483698609124125\ \(0\)\
\-\ of\\:\\ 0\\.0024876256398146997\ \(0\)\
\-\ the\\:\\ 0\\.002459951685117897\ \(0\)\
\-\ to\\:\\ 0\\.0015198153325373177\ \(0\)\
\-\ \\.\\:\\ 0\\.001515994424085962\ \(0\)\
\-\ a\\:\\ 0\\.0014113871950839903\ \(0\)\
\-\ with\\:\\ 0\\.0012491549048742677\ \(0\)\
